Every Form 4 that CytoMed Therapeutics Limited (GDTC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GDTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GDTC filings page.
CytoMed Therapeutics Ltd director and 10% owner Choo Chee Kong purchased 200,000 ordinary shares in July 2026 through two purchases in open market or private transactions at $1.50 per share on July 14 and July 20.
A Form 4/A amendment corrects the acquisition/disposition indicator to show these as acquisitions, and the Rule 10b5-1 box is unchecked, so the trades are not affirmed as made under a trading plan.
CytoMed Therapeutics Ltd director and 10% owner Choo Chee Kong reported two non-derivative transactions in ordinary shares of CytoMed Therapeutics Limited. On July 20, 2026 and July 14, 2026, he recorded dispositions of 100,000 shares each at $1.50 per share. Both transactions are classified as direct ownership, and no post-transaction share balance is reported in this disclosure.
CytoMed Therapeutics Ltd director and ten percent owner Choo Chee Kong bought 112,000 Ordinary Shares in an open-market purchase at $1.1498 per share. After this transaction, he directly owns 430,324 Ordinary Shares with no derivative positions reported in this filing.